Literature DB >> 23363317

Molecular model of a soluble guanylyl cyclase fragment determined by small-angle X-ray scattering and chemical cross-linking.

Bradley G Fritz1, Sue A Roberts, Aqeel Ahmed, Linda Breci, Wenzhou Li, Andrzej Weichsel, Jacqueline L Brailey, Vicki H Wysocki, Florence Tama, William R Montfort.   

Abstract

Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP after binding nitric oxide, leading to smooth muscle relaxation and vasodilation. Impaired sGC activity is common in cardiovascular disease, and sGC stimulatory compounds are vigorously sought. sGC is a 150 kDa heterodimeric protein with two H-NOX domains (one with heme, one without), two PAS domains, a coiled-coil domain, and two cyclase domains. Binding of NO to the sGC heme leads to proximal histidine release and stimulation of catalytic activity. To begin to understand how binding leads to activation, we examined truncated sGC proteins from Manduca sexta (tobacco hornworm) that bind NO, CO, and stimulatory compound YC-1 but lack the cyclase domains. We determined the overall shape of truncated M. sexta sGC using analytical ultracentrifugation and small-angle X-ray scattering (SAXS), revealing an elongated molecule with dimensions of 115 Å × 90 Å × 75 Å. Binding of NO, CO, or YC-1 had little effect on shape. Using chemical cross-linking and tandem mass spectrometry, we identified 20 intermolecular contacts, allowing us to fit homology models of the individual domains into the SAXS-derived molecular envelope. The resulting model displays a central parallel coiled-coil platform upon which the H-NOX and PAS domains are assembled. The β1 H-NOX and α1 PAS domains are in contact and form the core signaling complex, while the α1 H-NOX domain can be removed without a significant effect on ligand binding or overall shape. Removal of 21 residues from the C-terminus yields a protein with dramatically increased proximal histidine release rates upon NO binding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23363317      PMCID: PMC3607398          DOI: 10.1021/bi301570m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  60 in total

1.  Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.

Authors:  Sabine Meurer; Sylke Pioch; Tatjana Pabst; Nils Opitz; Peter M Schmidt; Tobias Beckhaus; Kristina Wagner; Simone Matt; Kristina Gegenbauer; Sandra Geschka; Michael Karas; Johannes-Peter Stasch; Harald H H W Schmidt; Werner Müller-Esterl
Journal:  Circ Res       Date:  2009-05-28       Impact factor: 17.367

2.  In-depth analysis of tandem mass spectrometry data from disparate instrument types.

Authors:  Robert J Chalkley; Peter R Baker; Katalin F Medzihradszky; Aenoch J Lynn; A L Burlingame
Journal:  Mol Cell Proteomics       Date:  2008-07-24       Impact factor: 5.911

3.  More than a retrograde messenger: nitric oxide needs two cGMP pathways to induce hippocampal long-term potentiation.

Authors:  Feras Taqatqeh; Evanthia Mergia; Angela Neitz; Ulf T Eysel; Doris Koesling; Thomas Mittmann
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

4.  Biased coarse-grained molecular dynamics simulation approach for flexible fitting of X-ray structure into cryo electron microscopy maps.

Authors:  Ivan Grubisic; Maxim N Shokhirev; Marek Orzechowski; Osamu Miyashita; Florence Tama
Journal:  J Struct Biol       Date:  2009-10-02       Impact factor: 2.867

5.  Binding of YC-1 or BAY 41-2272 to soluble guanylyl cyclase induces a geminate phase in CO photolysis.

Authors:  Xiaohui Hu; Changjian Feng; James T Hazzard; Gordon Tollin; William R Montfort
Journal:  J Am Chem Soc       Date:  2008-11-26       Impact factor: 15.419

Review 6.  Structure and signaling mechanism of Per-ARNT-Sim domains.

Authors:  Andreas Möglich; Rebecca A Ayers; Keith Moffat
Journal:  Structure       Date:  2009-10-14       Impact factor: 5.006

Review 7.  Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.

Authors:  Jaques Belik
Journal:  Curr Opin Investig Drugs       Date:  2009-09

Review 8.  Bridging the solution divide: comprehensive structural analyses of dynamic RNA, DNA, and protein assemblies by small-angle X-ray scattering.

Authors:  Robert P Rambo; John A Tainer
Journal:  Curr Opin Struct Biol       Date:  2010-01-22       Impact factor: 6.809

9.  Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  Joachim Mittendorf; Stefan Weigand; Cristina Alonso-Alija; Erwin Bischoff; Achim Feurer; Michael Gerisch; Armin Kern; Andreas Knorr; Dieter Lang; Klaus Muenter; Martin Radtke; Hartmut Schirok; Karl-Heinz Schlemmer; Elke Stahl; Alexander Straub; Frank Wunder; Johannes-Peter Stasch
Journal:  ChemMedChem       Date:  2009-05       Impact factor: 3.466

Review 10.  Structural and mechanistic aspects of flavoproteins: electron transfer through the nitric oxide synthase flavoprotein domain.

Authors:  Dennis J Stuehr; Jesús Tejero; Mohammad M Haque
Journal:  FEBS J       Date:  2009-07-03       Impact factor: 5.542

View more
  27 in total

1.  Instability in a coiled-coil signaling helix is conserved for signal transduction in soluble guanylyl cyclase.

Authors:  Andrzej Weichsel; Jessica A Kievenaar; Roslyn Curry; Jacob T Croft; William R Montfort
Journal:  Protein Sci       Date:  2019-08-27       Impact factor: 6.725

2.  Nitric oxide-induced conformational changes in soluble guanylate cyclase.

Authors:  Eric S Underbakke; Anthony T Iavarone; Michael J Chalmers; Bruce D Pascal; Scott Novick; Patrick R Griffin; Michael A Marletta
Journal:  Structure       Date:  2014-02-20       Impact factor: 5.006

3.  Single-particle EM reveals the higher-order domain architecture of soluble guanylate cyclase.

Authors:  Melody G Campbell; Eric S Underbakke; Clinton S Potter; Bridget Carragher; Michael A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

Review 4.  Redox regulation of soluble guanylyl cyclase.

Authors:  Rohan C Shah; Subramaniam Sanker; Katherine C Wood; Brittany G Durgin; Adam C Straub
Journal:  Nitric Oxide       Date:  2018-03-22       Impact factor: 4.427

5.  Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.

Authors:  Arnab Ghosh; Dennis J Stuehr
Journal:  Antioxid Redox Signal       Date:  2016-05-02       Impact factor: 8.401

6.  Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase.

Authors:  Jessica A Wales; Cheng-Yu Chen; Linda Breci; Andrzej Weichsel; Sylvie G Bernier; James E Sheppeck; Robert Solinga; Takashi Nakai; Paul A Renhowe; Joon Jung; William R Montfort
Journal:  J Biol Chem       Date:  2017-12-08       Impact factor: 5.157

7.  Heat Shock Protein 90 Associates with the Per-Arnt-Sim Domain of Heme-free Soluble Guanylate Cyclase: IMplications for Enzyme Maturation.

Authors:  Anindya Sarkar; Yue Dai; Mohammad Mahfuzul Haque; Franziska Seeger; Arnab Ghosh; Elsa D Garcin; William R Montfort; Stanley L Hazen; Saurav Misra; Dennis J Stuehr
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

8.  YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit.

Authors:  Rahul Purohit; Bradley G Fritz; Juliana The; Aaron Issaian; Andrzej Weichsel; Cynthia L David; Eric Campbell; Andrew C Hausrath; Leida Rassouli-Taylor; Elsa D Garcin; Matthew J Gage; William R Montfort
Journal:  Biochemistry       Date:  2013-12-30       Impact factor: 3.162

Review 9.  Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor.

Authors:  William R Montfort; Jessica A Wales; Andrzej Weichsel
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

10.  Inhibition of soluble guanylyl cyclase by small molecules targeting the catalytic domain.

Authors:  Jagamya Vijayaraghavan; Kristopher Kramp; Michael E Harris; Focco van den Akker
Journal:  FEBS Lett       Date:  2016-10-04       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.